Diagnosis and Classification of AML: WHO 2016

Voso, Maria Teresa; Bellis, Eleonora De; Ottone, Tiziana

doi:10.1007/978-3-030-72676-8_2

Cited by 1 publication

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now understood that approximately 55% of adult AML and 75% of pediatric AML is driven by a cytogenetic aberration ( 3 – 5 ). Presently, assessment of cytogenetic abnormalities is performed by karyotyping and fluorescent in situ hybridization for specific recurrent rearrangements of clinical significance ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

“…Importantly, FLT3 is a targetable tyrosine kinase receptor. The addition of FLT3 -targeting tyrosine kinase inhibitors has significantly improved the outcome of these patients ( 3 ). DNMT3A , along with other methylation associated genes including TET2 , IDH1 , and IDH2 , have been associated with poor prognosis in adults but are infrequently found in children ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Murine Models of Acute Myeloid Leukemia

et al. 2022

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a phenotypically and genetically heterogeneous hematologic malignancy. Extensive sequencing efforts have mapped the genomic landscape of adult and pediatric AML revealing a number of biologically and prognostically relevant driver lesions. Beyond identifying recurrent genetic aberrations, it is of critical importance to fully delineate the complex mechanisms by which they contribute to the initiation and evolution of disease to ultimately facilitate the development of targeted therapies. Towards these aims, murine models of AML are indispensable research tools. The rapid evolution of genetic engineering techniques over the past 20 years has greatly advanced the use of murine models to mirror specific genetic subtypes of human AML, define cell-intrinsic and extrinsic disease mechanisms, study the interaction between co-occurring genetic lesions, and test novel therapeutic approaches. This review summarizes the mouse model systems that have been developed to recapitulate the most common genomic subtypes of AML. We will discuss the strengths and weaknesses of varying modeling strategies, highlight major discoveries emanating from these model systems, and outline future opportunities to leverage emerging technologies for mechanistic and preclinical investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%